MLS Bio - Molecular Life Sciences Biotech (formerly ESfAM)

MLS Bio. Multi-asset biopharmaceutical company focused on pioneering next-generation therapies

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Melbourne VIC, Australia
  • Currency AUD
  • Founded December 2016
  • Employees 3
  • Incorporation Type C-corp
  • Website mlsbio.com

Company Summary

MLS Bio discovered a new cellular target (a new way to treat diseases) and developed 2 small molecules (2 new drugs) using the new target - treating Cancer & Infectious diseases. MLS 269 Cancer-agnostic applications 2nd MLS 289 has broad-spectrum antiviral activity. Globally recognised scientific leadership, US Scientific Advisory Board, wholly owned IP, AUS & US Patent, Pre IND-FDA approvals, significant pipeline. A series investors in DD.

Team

  • Penelope Lane
    MLS Bio Chief Executive Officer & Managing Director

    A global business leader in the commercialisation of Bio & Med Tech. MD, CEO, Advisor & NED. Prior leadership roles with multinational Pharma & MedTech, leading Universities, Government & Healthcare including the WHO. Led & exited 2 early R & D companies to global MedTech. Advisory boards; Sheba Medical Centre, Israel; Swinburn Uni & RMIT. Founder Vert & Or Advisory, Angel investor focus on Bio & MedTech & healthcare impact & equity of access

  • ALBERT FRAUMAN
    Founder and Chief Medical Officer & Executive Director

    Chair of the Department of Clinical Pharmacology and Therapeutics and Research Integrity advisor for Austin Health.
    Professor of Clinical Pharmacology & Therapeutics at The University of Melbourne since 2007.
    Practicing Endocrinologist at Austin Health.
    Served as Medical Director of Nucleus Network.
    Over 70 peer-reviewed publications in autoimmunity, viral infection and biomarkers of cancer progression, globally cited research expert.

  • Thomas Collins
    Chief Financial Officer & Financial Controller

    Globally Accredited & Experienced CFO & Controller.
    Global positions; Sheridan Pacific Brands, Coleman Brands, Pure Fishing ANZ, Jarden. NED, Chairman Berowra & District Financial Services
    Committed to adding value as part of commercially minded leadership teams. Expertise in the economics of business and company processes to grow sales & profit margins focused on prosperity in partnership & shared value.

  • Paul Scagliotti
    Company Secretary; Head of Law, Risk & Governance and Chief Operating Officer.

    Commercially oriented lawyer; skilled in technical & regulated health tech commercialisation industries. Commerce, Law & Masters health law qualifications, member of the Governance Institute of Aus. Experienced in law, governance & risk mitigation in early-stage health, medical & life sciences tech. Prior engagements: DLA Piper, Mills Oakley, Concepta Private Equity, ResMed, UNSW Wesfarmers Health, Uni of NSW, Monash Uni , La Trobe & RMIT.

Advisors

Previous Investors

  • Adrian Hondros
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free